The Antiviral Nucleotide Analogs Cidofovir and Adefovir Are Novel Substrates for Human and Rat Renal Organic Anion Transporter 1

TOMAS CIHLAR, DEBORAH C. LIN, JOHN B. PRITCHARD, MICHAEL D. FULLER, DIRK B. MENDEL, and DOUGLAS H. SWEET

Gilead Sciences, Foster City, California (T.C., D.L., M.D.F., D.B.M.); and Laboratory of Pharmacology and Chemistry, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina (J.B.P., D.H.S)

Received April 5, 1999; accepted June 17, 1999

This paper is available online at http://www.molpharm.org

ABSTRACT

Nephrotoxicity is the dose-limiting clinical adverse effect of cidofovir and adefovir, two potent antiviral therapeutics. Because renal uptake likely plays a role in the etiology of cidofovir- and adefovir-associated nephrotoxicity, we attempted to identify a renal transporter capable of interacting with these therapeutics. A cDNA clone was isolated from a human renal library and designated human organic anion transporter 1 (hOAT1). Northern analysis detected a specific 2.5-kilobase pair hOAT1 transcript only in human kidney. However, reverse transcription-polymerase chain reaction revealed hOAT1 expression in human brain and skeletal muscle, as well. Immunoblot analysis of human kidney cortex revealed that hOAT1 is an 80- to 90-kilodalton heterogeneous protein modified by abundant N-glycosylation. Xenopus laevis oocytes expressing hOAT1 supported probenecid-sensitive uptake of [3H]p-aminohippurate ($K_m = 4 \mu M$), which was trans-stimulated in oocytes preloaded with glutarate. Importantly, both hOAT1 and rat renal organic anion transporter 1 (rROAT1) mediated saturable, probenecid-sensitive uptake of cidofovir, adefovir, and other nucleoside phosphonate antivirals. The affinity of hOAT1 toward cidofovir and adefovir ($K_m = 46$ and $30 \mu M$, respectively) was 5- to 9-fold higher compared with rROAT1 ($K_m = 238$ and $270 \mu M$, respectively). These data indicate that hOAT1 may significantly contribute to the accumulation of cidofovir and adefovir in renal proximal tubules and, thus, play an active role in the mechanism of nephrotoxicity associated with these antiviral therapeutics.

Successful management of viral infections often requires long-term therapy with highly potent antivirals. However, various adverse effects may be induced by prolonged administration of antiviral drugs. For example, long-term azidothymidine and dideoxycytidine therapy causes myopathy and peripheral neuropathy, respectively, in a number of AIDS patients (Dalakas et al., 1990; Dubinsky et al., 1989). Similarly, extended therapy with HIV protease inhibitors may be associated with peripheral lipodystrophy, hyperlipidemia, and insulin-resistant diabetes (Carr et al., 1998). However, the main dose-limiting clinical factor for cidofovir ([S]-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine) and adefovir [9-(2-phosphonylmethoxyethyl)adenine], two potent antiviral agents with unique resistance profiles, is nephrotoxicity characterized by changes in laboratory markers of renal function (Lalezari et al., 1997; Fisher et al., 1999). Both cidofovir and adefovir are nucleoside phosphonate analogs, a class of novel antivirals structurally related to natural nucleotides (Fig. 1). Cidofovir is a potent inhibitor of almost all types of DNA viruses (Hitchcock et al., 1996) and has been approved for treatment of cytomegalovirus retinitis in AIDS patients. Adefovir showed a strong in vitro effect against herpesviruses, hepadnaviruses, and retroviruses (Cihlar and Bischofberger, 1998). Its orally available prodrug is currently being evaluated as an anti-HIV agent in phase III clinical studies. In addition, clinical trials exploring the application of adefovir as a treatment for hepatitis B virus infections are under way.

Cidofovir and adefovir are actively secreted by the kidney (Cundey et al., 1995a,b), suggesting that active drug accumu-
lation in renal proximal tubules may play a role in the etiology of the drug-associated nephrotoxicity. In rabbits and rats, cidofovir is accumulated in kidney, reaching significantly higher concentration levels compared with other organs and tissues (Cundy et al., 1996a,b). Presumably, the uptake of cidofovir across the basolateral tubular membrane is more efficient than the subsequent secretion into tubular lumen resulting in drug accumulation in renal tubules. Hence, inhibition of the active drug uptake into proximal tubular cells may provide an effective strategy to ameliorate the renal toxicity syndromes. Previously this approach has been shown to be effective for some nephrotoxic β-lactam antibiotics. For example, N-benzoyl-β-alanine (betamipron) has been shown to reduce the nephrotoxicity of cephaloridine by inhibiting its tubular uptake (Tune, 1997). Similarly, in cynomolgus monkeys receiving chronic i.v. cidofovir treatment, coadministration of oral probenecid, an inhibitor of renal organic anion transport, reduced the incidence and severity of the drug-associated nephrotoxicity (Lacy et al., 1998b). Thus, identification and characterization of renal transporter(s) that mediate tubular uptake of cidofovir and/or adeovir would contribute to a better understanding of the mechanisms of their nephrotoxicity, as well as aid in the design of novel, specific, and effective nephroprotective agents.

The renal organic anion transport system, because of its sensitivity to probenecid and broad substrate specificity, is a primary candidate to mediate uptake of nucleoside phosphate analogs into proximal tubules. Probenecid-sensitive renal organic anion transporters from rat (rROAT1/rOAT1), mouse (mNKT/mROAT1), and winter flounder (fROAT1) have been previously cloned and characterized (Lopez-Nieto et al., 1997; Sekine et al., 1997; Sweet et al., 1997; Wolff et al., 1997). Upon expression in Xenopus oocytes, rROAT1 functions as an organic anion/dicarboxylate exchanger and mediates uptake of p-aminohippurate (PAH), cyclic nucleotides, and other small organic anions, indicating its broad substrate specificity (Sekine et al., 1997; Sweet et al., 1997). Upon expression in Xenopus oocytes, rROAT1 functions as an organic anion/dicarboxylate exchanger and mediates uptake of p-aminohippurate (PAH), cyclic nucleotides, and other small organic anions, indicating its broad substrate specificity (Sekine et al., 1997; Sweet et al., 1997). rROAT1 clearly represents the multispecific PAH/dicarboxylate exchanger previously detected by functional studies in basolateral membrane vesicles and isolated renal proximal tubules from a variety of species (Pritchard, 1988). In this study, we report the cloning and characterization of a human organic anion transporter, hOAT1, and demonstrate its function as a PAH/dicarboxylate exchanger. Importantly, we present data indicating that several antiviral nucleoside phosphate analogs are high-affinity substrates for hOAT1 and that this transporter may be directly involved in mediating cidofovir- and adeovir-associated nephrotoxicity.

Materials and Methods

**Screening of a Human Renal cDNA Library.** A human kidney cDNA library was purchased from Invitrogen (Carlsbad, CA) and screened by colony hybridization with a 42-mer oligonucleotide (5’-CACGGCCGCCGCGGCTCCGATGGCCAACCTCAGCAAGAACGGG-3’) corresponding to the 5’-end of clone expressed sequence tag (EST)58612 (GenBank accession number AA351032). The oligonucleotide was labeled with [32P]dATP using T4 polynucleotide kinase. Bacterial colonies were transferred onto Hybond-N membranes (Amersham Pharmacia Biotech, Arlington Heights, IL) and hybridized overnight with the labeled probe in hybridization buffer (5× standard saline citrate (SSC), 5× Denhardt’s solution, 0.05% SDS) at 68°C. Final washing was performed twice with 0.1× SSC + 0.1% SDS. Filters were subjected to autoradiography overnight, and several positive colonies were identified. Plasmid DNA was purified from these clones, and the length of their cDNA inserts determined by polymerase chain reaction (PCR).

**DNA Sequencing and Analysis.** The clone containing the largest cDNA insert (pOAT-8) was subjected to complete sequence analysis of both complementary strands by simultaneous “walking” from the 5’- and 3’-ends of the insert. Automatic sequencing was performed with Cy5-labeled oligonucleotide primers (Integrated DNA Technologies, Coralville, IA) using the Thermosequenase cycle sequencing kit (Amersham Pharmacia Biotech). All ambiguities were resolved by manual sequencing using the Thermosequenase radioactive labeled terminator cycle sequencing kit (Amersham Pharmacia Biotech). If necessary, dideoxy-ITP was substituted for dideoxy-GTP to resolve sequence compressions. Initially, a BLAST search of the GenBank database identified mNKT/mROAT1 and rROAT1 as being related sequences, but no human homologs were found, and we designated this cDNA clone as hOAT1. All DNA and peptide sequence comparisons and database searches were done with the Wisconsin Package software (Genetics Computer Group, Madison, WI) with default settings.

**Northern Blotting.** A human multiple tissue Northern blot (CLONTECH, Palo Alto, CA) was used for localization of hOAT1 expression in human tissues. An hOAT1-specific [32P]dATP-labeled probe was generated by random priming the BsrGI/BsaI DNA fragment from pOAT-8 (nucleotides 420–854 of hOAT1 coding region). The membrane was hybridized for 1 h at 68°C in ExpressHyb hybridization buffer (CLONTECH) and then washed twice in 2× SSC with 0.05% SDS for 30 min at room temperature followed by a single wash in 0.1× SSC with 0.1% SDS at 50°C. The membrane was autoradiographed for 7 days at −70°C with intensifying screens. After stripping, the membrane was reprobed with a β-actin control probe provided by the manufacturer and autoradiographed for 3 h.

**Tissue Localization by Reverse Transcription (RT)-PCR.** The multiple choice cDNA kits I and II containing tissue-specific cDNAs (Origene Technologies, Rockville, MD) and two sets of hOAT1-specific primers were used for PCR detection of hOAT1 expression. The oligonucleotides, 5’-CCCGCTTGCGACACTTCTCCGAGGAG-3’ (sense), and 5’-GTAGACGTTCGCGACGTCTACCCAGCGCA-3’ (antisense), were used to amplify a 606-bp fragment from the hOAT1 coding region (nucleotides 815–1420). In the independent set of PCR reactions, a 255-bp hOAT1 fragment (composed of the last 175 coding nucleotides and 120 nucleotides of the 3’-untranslated region (UTR)) was amplified using the oligonucleotides, 5’-CACGGCGTGCTAGCTGCTGCTGCTCAGG-3’ (sense), and 5’-AACCCCCACACTTGTTGACACATC-3’ (antisense).

PCR reactions were carried out using the Expand High Fidelity PCR system (Roche Molecular Biochemicals) in a total volume of 25 μL containing 1 μg of tissue-specific cDNA. Thirty-five amplification cycles (95°C for 40 s, 55°C for 1 min, and 72°C for 45 s) were

![Fig. 1. Structure of acyclic nucleoside phosphate analogs.](image-url)
performed. A negative control without cDNA template was included in each set of reactions. As an internal control, a β-actin fragment was amplified using primers provided by the manufacturer.

In Vitro Expression of hOAT1. For efficient in vitro expression of hOAT1, the plasmid pOAT-8/TTT was constructed as follows. A fragment containing the first 500 bp of the hOAT1 coding region was amplified from pOAT-8 by the PCR using the sense primer 5'-ATGCCCTGGATCCAGCTTTATTTAGGTCAGCTATAGAATACTCACAGCTGTATTATTTTTATTTCAGCAATCTCAGAGTCCCTAATAGAATCCT-3' to introduce a BamHI restriction site, the SP6 promoter, a truncated form of the 5'-UTR from alfalfa mosaic virus, and a favorable initiation context (these elements are underlined in the same order in the primer sequence). The oligonucleotide 5'-CGATGCTGGCCTGGCTTGCCCAGATGTCAGCCT-3' was used as an antisense primer. The PCR product was digested with BamHI and BsrGI, and subcloned into BamHI/BsrGI-digested pOAT-8. Plasmid pOAT-8/TTT was expressed in vitro with the TNT SP6 Coupled Reticulocyte Lysate system (Promega, Madison, WI). A 25-μl reaction, containing 2 μg of circular plasmid and other components according to the manufacturer’s protocol including complete amino acid mixture, was incubated for 2 h at 30°C and subjected to immunoblot analysis as described below.

Immunoblot Analysis of hOAT1. Rabbit anti-hOAT1 polyclonal antibody was prepared at AnaSpec (San Jose, CA) using standard immunological techniques. Briefly, a peptide corresponding to hOAT1 amino acids 515 to 528 was conjugated to keyhole limpet hemocyanine through a cysteine residue added to the C terminus of the peptide. Animal serum was collected after four immunizations in the presence of complete Freund’s adjuvant and affinity-purified against the immunogenic peptide immobilized on a Sepharose resin.

For immunoblot analysis, human kidney cortex was obtained from the International Institute of Advanced Medicine (Exton, PA), frozen in liquid nitrogen, ground to a powder, and mixed with 10-fold excess (w/v) of extraction buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Nonidet P-40, 0.5% deoxycholate, 0.1% SDS). After homogenization in the presence of complete proteinase inhibitor cocktail (Roche Molecular Biochemicals) the extract was clarified by high-speed centrifugation. An aliquot was deglycosylated by incubation in the presence of peptide-a-N-glycosidase F (New England Biolabs, Beverly, MA) for 2 h at 37°C without prior denaturation. Tissue extracts (50 μg of protein) and in vitro expression reactions (10 μl) were separated by electrophoresis on an 8% SDS-polyacrylamide gel and electroblotted onto a nitrocellulose membrane (Millipore, Bedford, MA). The membrane was subsequently blocked in PBS/5% dry milk (PBS-M) for 1 h, washed three times in PBS/0.05% Tween 20, and incubated overnight in PBS-M with the anti-hOAT1 antibody. Following washing in PBS/0.05% Tween 20, the membrane was incubated in PBS-M with goat anti-rabbit antibody conjugated to horseradish peroxidase (Zymed, South San Francisco, CA). After an additional wash and incubation with a chemiluminescent substrate (Amersham Pharmacia Biotech), the immunoblot was exposed to X-ray film.

Xenopus Oocyte Expression Assay. For batch oocyte isolation, adult female Xenopus laevis (Xenopus One, Ann Arbor, MI) were anesthetized by hypothermia and decapitated. Ovaries were removed and divided into clumps of ~50 to 100 oocytes. Oocyte clumps were placed into a 50-ml conical tube containing oocyte Ringer’s 2 (OR-2: 82.5 mM NaCl, 2.5 mM KCl, 1 mM Na2HPO4, 3 mM NaOH, 1 mM CaCl2, 1 mM MgCl2, 1 mM pyruvic acid, and 5 mM HEPES, pH 7.6) until they reached the 4-ml mark. Oocytes were rinsed three times with 10 ml of calcium-free OR-2 (82.5 mM NaCl, 2 mM KCl, 1 mM MgCl2, and 5 mM HEPES, pH 7.6), placed in collagenase solution [5 mg/ml collagenase A (Roche Molecular Biochemicals) and 1 mg/ml trypsin inhibitor type III-O (Sigma Chemical Co., St. Louis, MO) in calcium-free OR-2] and stirred at 100 rpm for 2 to 2.5 h at 18°C. After collagenase treatment, the oocytes were rinsed five times with OR-2 containing 1 mg/ml BSA and placed in a phosphate/BSA solution for 1 h (100 mM K2HPO4 with 1 mg/ml BSA, pH 6.5). Oocytes were agitated every 15 min to remove the follicle and then rinsed five times with OR-2 + BSA. Stages V and VI oocytes were collected and maintained at 18°C in OR-2 containing 0.05 mg/ml gentamycin sulfate, 2.5 mM sodium pyruvate, and 5% heat-inactivated horse serum. Overnight recovery was allowed before injection.

Capped cRNA for microinjection was synthesized from linearized plasmid DNA using Ambion’s mMessage mMachine in vitro transcription kit (Ambion, Inc., Austin, TX). The cRNA products were quantitated in a spectrophotometer and diluted before injection to allow delivery of 20 ng of cRNA/oocyte in 16 nl with a 1- to 2-s injection.

Uptake assay was performed as described previously (Sweet et al., 1997). Briefly, 3 days after injection, the oocytes were divided into experimental groups (containing 10 oocytes each) and incubated at 18–22°C for 20 or 60 min in OR-2 containing various substrates in the absence or presence of inhibitors, as indicated in the figure legends. After uptake, oocytes were rapidly rinsed three times with ice-cold OR-2 and placed into individual scintillation vials containing 0.5 ml of 1 M NaOH, incubated at 65°C for 20 min, and neutralized with 0.5 ml of 1 M HCl. Finally, 4.7 ml of Eclumone (ICN Biomedical, Cleveland, OH) was added and radioactivity was determined in a Packard 1600TR liquid scintillation counter with external quench correction. Uptake was calculated in picomoles per oocyte.

Statistics. Data are presented as mean ± S.E. Differences in mean values were considered to be significant when p ≤ .05 as determined by one-sample or paired Student’s t test. The degree of significance was as indicated in the figure legends.

Chemicals. [3H]PAH (3.7 Ci/mmol) was obtained from NEN Life Science Products (Boston, MA). [14C]Tetraethylammonium (53 mCi/mmol) was obtained from American Radiolabeled Chemicals, Inc. (St. Louis, MO). Adefovir (30 Ci/mmol), cidovir (56 Ci/mmol), [3H]9-(2-phosphonylmethoxyethyl)guanine (PMEG; 34 Ci/mmol), and [3H]9-(2-phosphonylmethoxyethyl)diaminopurine (PMEDAP; 32 Ci/mmol) were purchased from Moravek Biochemicals (Brea, CA). All unlabeled nucleoside phosphonates were synthesized at Gilead Sciences according to previously published procedures (Holy and Rosenberg, 1987). Unlabeled PAH, probenicid, and glutarate were obtained from Sigma.

Results

Cloning of hOAT1 cDNA. To identify potential cDNA sequences encoding a hOAT homolog, a BLAST search of the GenBank EST database was performed with the full-length rROAT1 cDNA sequence (Sweet et al., 1997). Two EST cDNA clones from human infant brain tissue (accession number R25797 and AA351032), whose 5’-end regions exhibited a high level of sequence homology to rROAT1 between coding nucleotides 390 and 730, were identified. Therefore, an oligonucleotide probe derived from EST clone AA351032 was used to screen a human kidney cDNA library, and a positive clone was identified (pOAT-8). We refer to this cDNA clone as hOAT1.

Molecular Characterization of hOAT1. The complete DNA sequence of both strands of hOAT1 was determined, and the sense strand sequence is presented in Fig. 2A. The hOAT1 cDNA is 2118-bp long, including: 257 bp of 5’-UTR; a single, large open reading frame 1650-bp long; and 211 bp of 3’-UTR. The ATG at position 258 to 260 is the first start codon and has a correlation with Kozak’s consensus for the translation initiation (Kozak, 1987) giving a predicted protein length of 550 amino acids with a molecular mass of 60.3 kDa. Hydropathy analysis (Kyte and Doolittle, 1982) predicted 12 potential α-helical membrane-spanning domains with both the amino and carboxyl termini located intracellularly (Fig. 2). According to this analysis, there is a large extracellular loop between transmembrane domains 1 and 2. Within this loop are five potential N-linked glycosylation
Fig. 2. DNA and predicted amino acid sequence of hOAT1. A, complete nucleotide sequence of the sense strand of the hOAT1 cDNA and the predicted amino acid sequence of the single large open reading frame is shown. Approximate locations of the 12 predicted transmembrane domains are indicated below the predicted amino acid sequence. Potential N-linked glycosylation sites (p) and potential O-linked glycosylation sites (●) within the first extracellular loop are identified. Numbers to the left of the sequences indicate nucleotide and amino acid position, respectively. B, Kyte-Doolittle hydrophobicity plot. Proposed transmembrane domains are indicated by number.
sites at Asn39, Asn56, Asn92, Asn97, and Asn113 and four cysteine residues at positions 49, 78, 105, and 128 that could participate in disulfide bond formation (Fig. 2A). A significant intracellular loop between transmembrane domains 6 and 7, from approximately amino acid residues 271 to 336, contains four protein kinase C (PKC) consensus sites located at Ser271, Ser278, Thr284, and Thr334 and a potential casein kinase II (CKII) site at Ser325 (Fig. 2A). Finally, within the carboxy-terminal domain there is another putative PKC site at Thr521, two potential CKII sites at Thr515 and Ser543, and a tyrosine kinase consensus site at Tyr536. Whether any or all of these consensus sites participate in protein modification or function requires further experimentation.

During the course of our study, other reports have appeared in the literature concerning the cloning of hROATs designated hROAT1 (Reid et al., 1998), hOAT1–1 and hOAT1–2 (Hosoyamada et al., 1999), and human p-aminohippurate transporter (hPAHT) (Lu et al., 1999). Unfortunately, the DNA sequences for hOAT1–1 (accession number AB00697), hOAT1–2 (accession number AB00698), and hPAHT (no accession number reported) were not yet available in the GenBank database to compare with our hOAT1. Although there are some minor differences between our DNA sequence and that for hROAT1 (accession number AF057039), the predicted peptide sequence of our clone is identical with hROAT1 except for the final amino acid residue, Phe in hROAT1 versus Leu in hOAT1. At this time, no functional data has been published for hROAT1. Comparison with the published peptide sequence of hOAT1–2 confirms that our clone is the same, however, no characterization of hOAT1–2 was presented (Hosoyamada et al., 1999). Similarly, comparison with the published hPAHT sequence reveals that the sequence of our clone is identical except for the amino acid at position 14 (Ser in hPAHT versus Gly in hOAT1).

Alignment of the hOAT1 DNA sequence with hROAT1, rROAT1, mNKT(mROAT1), and rOAT1D showed a 99.7, 83.8, 83, and 59.5% identity, respectively. A summary of potential modification sites for these transporters is presented in Table 1. It is our opinion that hOAT1–2 and hPAHT have all of the same sites as those listed for hOAT1, yet, there was no mention of PKA, CKII, or tyrosine kinase (TK) consensus sites for hOAT1–2 (Hosoyamada et al., 1999) nor any CKII or TK sites for hPAHT (Lu et al., 1999). In contrast to our findings, Lu et al. (1999) reported four PKA consensus sites within the hPAHT sequence, however, these sites do not conform to the consensus used in our motif search (R,K2X(S,T)).

**Expression of hOAT1 in Human Tissues.** Northern blot analysis was used to examine hOAT1 expression in different human tissues with an hOAT1-specific DNA probe. A strong signal was detected in kidney corresponding to a transcript 2.5-kb in size (Fig. 3a, top). In addition, there was a very weak signal of about 3.5 kb in liver that was detectable only after prolonged exposure. No positive signal was found in heart, brain, skeletal muscle, colon, thymus, spleen, small intestine, placenta, lung, or peripheral blood leukocytes. The lack of a detectable signal in brain was an unexpected result because, as mentioned above, two EST clones from a human infant brain cDNA library were identified with sequence identical to a 340-bp region of hOAT1. Therefore, we used the more sensitive technique of RT-PCR amplification to examine hOAT1 expression in various human tissues. Each sample was analyzed independently using two distinct sets of primers with proper negative controls (Fig. 3B, top and middle). A strong positive signal was consistently detected in kidney with both sets of primers. In contrast with the Northern analysis, RT-PCR amplification consistently yielded a product from brain. Interestingly, a strong positive signal was also detected in skeletal muscle, although only with one set of hOAT1-specific primers.

**Immunoblot Analysis of hOAT1.** A polyclonal antibody was generated in rabbits immunized with a synthetic peptide derived from a region of hOAT1 with predicted high antigenicity. In the immunoblot analysis of an extract from human kidney cortex, the antibody recognized a heterogeneous product with an apparent molecular mass of approximately 80 to 90 kDa (Fig. 4). This was significantly larger than the predicted molecular mass from the hOAT1 amino acid sequence. However, when the cortex extract was treated with peptide/ N-glycosidase F, which specifically cleaves N-linked oligosaccharide chains, a 60-kDa homogeneous product was detected on the immunoblot. To determine whether this treatment completely removes all modifications from the hOAT1 peptide, we attempted to generate a control for the unmodified polypeptide by in vitro expression of hOAT1 cDNA in rabbit reticulocyte lysate. At first, no product of in vitro expression was detected in the presence of pOAT-8 plasmid. To achieve efficient expression, the original hOAT1 5'-UTR was replaced by a truncated form of the alfalfa mosaic virus RNA4

**TABLE 1**

<table>
<thead>
<tr>
<th>Gene (species)</th>
<th>% Identity with hOAT1</th>
<th>Conserved cysteine residues</th>
<th>N-linked glycosylation consensus sites</th>
<th>PKA</th>
<th>PKC</th>
<th>CKII</th>
<th>TK</th>
</tr>
</thead>
<tbody>
<tr>
<td>hOAT1/ROAT1 (human)</td>
<td>49, 78, 105, 128</td>
<td>39, 56, 92, 97, 113</td>
<td>Ser271, Ser278, Thr284, Thr334, Ser325, Thr515, Ser543</td>
<td>Ser325, Thr515, Ser543</td>
<td>Ser538</td>
<td></td>
<td></td>
</tr>
<tr>
<td>rROAT1/OAT1 (rat)</td>
<td>88</td>
<td>49, 78, 105, 128</td>
<td>39, 56, 92, 97, 113</td>
<td>Ser271, Ser278, Thr284, Thr334, Ser325, Thr515, Ser543</td>
<td>Ser538</td>
<td></td>
<td></td>
</tr>
<tr>
<td>mNKT (mROAT1) (mouse)</td>
<td>86</td>
<td>49, 78, 99, 122</td>
<td>39, 56, 96, 91, 107</td>
<td>Ser271, Ser278, Thr284, Thr334, Ser325, Thr515, Ser543</td>
<td>Ser538</td>
<td></td>
<td></td>
</tr>
<tr>
<td>fROAT (winter flounder)</td>
<td>49</td>
<td>49, 81, 117, 140</td>
<td>54, 95, 124</td>
<td>Ser271, Ser278, Thr284, Thr334, Ser325, Thr515, Ser543</td>
<td>Ser538</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Potential modification sites for transport proteins with the corresponding amino acid position numbers within their respective polypeptide chains. Boldface denotes positions conserved between homologs, underline denotes positions conserved within mammals, and italics denotes sites unique to hOAT1.

Downloaded from molpharm.aspetjournals.org on June 21, 2017.
5'-UTR, which has been previously shown to significantly stimulate in vitro expression in reticulocyte lysate (Cihlar et al., 1997). In addition, the sequence surrounding the starting ATG codon was modified to match an optimal initiation context (Kozak, 1987). As shown in Fig. 4, the modified plasmid yielded a single polypeptide whose size was identical to that of the deglycosylated hOAT1. Together, these findings indicate that hOAT1 is modified by abundant N-glycosylation, which could account for up to 30% of its total molecular weight. Importantly, because all potential N-glycosylation sites reside within the large loop between the first and second putative transmembrane domain, it also shows that this loop is indeed located extracellularly as predicted from the hOAT1 hydropathy plot.

**Functional Characterization of hOAT1 Transport.** That the hOAT1 cDNA does indeed encode an organic anion transporter was confirmed by *Xenopus* oocyte expression assay. After cRNA injection, hOAT1-mediated uptake of 50 μM [3H]PAH was equivalent to that seen with the previously identified basolateral organic anion transporter rROAT1 (Fig. 5; Sweet et al., 1997). Addition of 1 mM probenecid reduced PAH uptake by 98%, proving that virtually all of the uptake was carrier mediated. Water-injected oocytes showed no appreciable uptake and were unaffected by probenecid.

The effects of various compounds and reduced temperature on hOAT1-mediated PAH uptake were also examined (Fig. 6). The organic anions probenecid, α-ketoglutarate (α-KG), bromcresol green, and 2,4-dichlorophenoxyacetic acid, as
well as excess unlabeled PAH, each reduced [3H]PAH uptake by at least 95% at 1 mM concentration. Interestingly, unlike the results reported for rROAT1 (Sweet et al., 1997), the organic anion urate (1 mM) was a fairly effective inhibitor of hOAT1, reducing PAH uptake by 75%; however, when used as substrate, there was no detectable transport of urate (data not shown). Transport was unaffected by the cation tetraethylammonium (1 mM) or by the P-glycoprotein inhibitor cyclosporin-A (10 μM). Furthermore, the ability of α-KG to inhibit PAH uptake is indicative of a basolateral location for hOAT1, because the basolateral dicarboxylate/organic anion exchanger (e.g., rROAT1) should be inhibited by external α-KG as opposed to the luminal PAH carriers, which should be insensitive to this inhibition (Pritchard and Miller, 1993).

rROAT1 has been shown to function as a basolateral dicarboxylate/organic anion exchanger. If hOAT1 functions in the same way in human kidney, increasing the intracellular concentration of dicarboxylate should induce trans-stimulation of exogenous substrate uptake (Pritchard and Miller, 1993). For this determination, glutarate is the preferred counterion, because, in contrast to α-KG, it is not extensively metabolized (Pritchard, 1990). As shown in Fig. 7, incubating the oocytes in 5 mM glutarate for 90 min before exposure to PAH (i.e., preloading) significantly (p < .0001) stimulated PAH uptake in hOAT1-expressing oocytes, as compared with nonpreloaded oocytes. Moreover, glutarate preloading had no effect on water-injected oocytes (data not shown). Thus, glutarate induced trans-stimulation of hOAT1-mediated PAH uptake, suggesting that the uptake occurs in conjunction with the countertransport of dicarboxylate.

**Nucleoside Phosphonate Analogs Are High-Affinity Substrates for hOAT1.** Finally, the ability of rROAT1 and hOAT1 to mediate the transport of therapeutically important antiviral nucleoside phosphonates was tested. Together with adefovir (10 μM) and cidofovir (36 μM), two other nucleoside phosphonates with broad-spectrum antiviral and antiproliferative activity, PMEG (10 μM) and PMEDAP (10 μM), were found to be substrates for both rROAT1 and hOAT1 (Fig. 8). However, uptake of all antivirals tested was markedly higher for hOAT1 compared with rROAT1. Little to no uptake was measured in water-injected oocytes, indicating the complete lack of diffusive uptake of these nucleotide analogs. Like PAH, both hOAT1- and rROAT1-mediated uptake of all nucleoside phosphonates was efficiently blocked by 1 mM probenecid. In contrast to hOAT1 and rROAT1, the renal organic cation transporter 2, did not mediate detectable uptake of adefovir or cidofovir in renal organic cation transporter 2 cRNA-injected oocytes (data not shown). Finally, similar to PAH, preloading the oocytes in 5 mM glutarate for 90 min before exposure to adefovir significantly stimulated adefovir uptake in rROAT1 (5.3-fold increase, p < .001) and hOAT1 (1.5-fold increase, p < .01)-expressing oocytes, as compared with nonpreloaded oocytes. Thus, hOAT1-mediated adefovir uptake correlates with the countertransport of dicarboxylate.

To find out whether the marked dissimilarity between rROAT1 and hOAT1 transport of nucleoside phosphonates is simply due to different levels of expression of the two transporters or actually due to lower substrate affinity of rROAT1, Km values for cidofovir and adefovir were determined. Adefovir and cidofovir uptake by hOAT1-expressing oocytes increased steadily with time and was linear for about 1 h (data not shown). Using a 20-min incubation period to approximate initial rate, the transport was assessed by incubating cRNA-injected oocytes in medium containing 0.002 to 1 mM substrate concentrations. Double reciprocal plots of the saturation data were constructed, and linear regression analysis was performed to obtain Km estimates (Fig. 9). Adefovir and cidofovir exhibited Km values of 30 and 46 μM, respectively, for hOAT1-mediated transport (Table 2). However, the corresponding Km values for rROAT1-mediated transport were 5- and 9-fold higher, respectively, compared with hOAT1. A significant difference in Km values between the two transporters was also observed for PAH (Table 2).

**Fig. 6.** Inhibition profile of hOAT1-mediated PAH uptake. cRNA from hOAT1 was injected into oocytes, and 50 μM [3H]PAH transport was measured after 60 min in the presence of several organic anions and cations. Data are presented as percentage of control uptake. Values are mean ± S.E. for two animals (10 oocytes/treatment/animal). *p ≤ .05, **p ≤ .01, and ***p ≤ .001, as determined by one sample Student’s t test.
Besides other important functions, the kidney plays an indispensable role in maintaining body homeostasis, and it is highly specialized for this purpose. Its functional unit, the nephron, is a polarized epithelium equipped with transport systems that mediate active secretion and/or reabsorption of a variety of small molecules. For drugs and other foreign compounds, secretion is achieved through coordinated function of basolateral and apical transporters operating in series (Pritchard and Miller, 1993). The elimination of some drugs and xenobiotics is so effective that they are completely cleared from renal plasma in a single pass through the kidney. Because the kidney handles one-fifth of the entire cardiac output, proximal tubular epithelium must possess a remarkable transport capacity. This has a significant implication for drug therapy, because the secretory transport may lead to an active drug accumulation within proximal tubular cells with associated risk of nephrotoxicity. Animal toxicology and pharmacokinetic studies suggested that such mechanisms may also be involved in the nephrotoxicity induced by cidofovir and adefovir therapy. In this study, we have cloned and expressed hOAT1 and shown that it exhibits a high affinity toward these clinically important antivirals.

The clone hOAT1 is virtually identical with a human clone identified as hROAT1 by Reid et al. (1998), differing only in the terminal amino acid, Phe in hROAT1 versus Leu in hOAT1. Notably, Leu has been reported as the final amino acid in the terminal region of hOAT1.
acid in rROAT1, mNKT(mROAT1), hOAT1–1, hOAT1–2, and hPAHT. The recent study by Lu et al. (1999) describes the isolation of hPAHT, which differs from hOAT1 at position 14 (Gly in hOAT1 versus Ser in hPAHT). In this instance, rROAT1, mNKT(mROAT1), hOAT1–2, hROAT1, and even fROAT, all have Gly at position 14. These two sequence differences may be the result of PCR errors introduced by the method used to clone hROAT1 and hPAHT. hOAT1 also appears to be the same clone as that designated as hOAT1–2 by Hosoyamada et al. (1999). However, the transport properties of hOAT1–2 were not characterized in the study. Finally, a fourth closely related human clone was designated as hOAT1–1 by Hosoyamada et al. (1999), which differs from hOAT1–2 by an extra 13 amino acid stretch in the C terminus.

The presence of hOAT1-specific mRNA was detected in human kidney as well as brain when the sensitive technique of RT-PCR amplification was used. Similarly, presence of mouse OAT1/NKT-specific mRNA has been localized to kidney as well as brain (Lopez-Nieto et al., 1997). However, although organic anion transport activity has been previously detected in choroid plexus (Miller and Ross, 1976), presence of hOAT1 protein as well as its precise localization and function in brain remains to be elucidated.

Characterization of hOAT1 in Xenopus oocytes indicated that, like rROAT1, it functions as a PAH/dicarboxylate exchanger. Specifically, it mediates PAH accumulation, which was effectively inhibited by a variety of organic anions, including urate (although urate itself was not a substrate). Importantly, substrate uptake into oocytes was trans-stimulated by glutarate, indicating that hOAT1 mediates dicarboxylate/organic anion exchange (Fig. 7). This is consistent with a role of hOAT1 in basolateral uptake of anionic drugs from the plasma, as previously established for rROAT1 (Pritchard, 1988; Sekine et al., 1997; Sweet et al., 1997). However, it must be noted that unlike rat kidney, the human kidney appears capable of dicarboxylate/organic anion exchange at luminal as well as basolateral membranes (Roch-Ramel et al., 1996). Kidney tissue immunostaining revealed predominant, if not exclusive, localization of hOAT1–1 in the basolateral membrane of the proximal tubule (Hosoyamada et al., 1999). However, in either location, basolateral or apical, the in vivo orientation of the dicarboxylate gradient (in > out) (Pritchard and Miller, 1993) dictates that hOAT1 must mediate cellular uptake of its exogenous substrates.

We showed that four antiviral nucleoside phosphonate analogs were substrates for hOAT1 (Table 2 and Fig. 8). Interestingly, hOAT1 has significantly higher affinity to nucleoside phosphonates compared with rROAT1. This may explain, in part, the observation that a higher dose of adefovir is required to induce nephrotoxicity syndromes in rats (Lacy et al., 1998a) compared with humans (Fisher et al., 1999). If hOAT1 is involved in cidofovir- and/or adefovir-associated nephrotoxicity, these drugs should show their highest renal accumulation in those segments of the proximal tubule expressing the organic anion/dicarboxylate exchanger. In rabbits, PAH/dicarboxylate transport activity is most abundantly expressed in the S2 segment of proximal tubule (Shpun et al., 1995). Furthermore, in situ hybridization using a specific cRNA probe demonstrated high levels of rROAT1 expression in the S2 segment of rat renal proximal tubules (Sekine et al., 1997). Notably, rabbits show the highest accumulation of cidofovir in the most superficial part of cortex (Cundy et al., 1996b), which contains S1 and S2 proximal tubular segments, suggesting that cidofovir accumulation does colocalize with expression of the basolateral organic anion/dicarboxylate exchanger (i.e., rROAT1 and by infer-

**Fig. 9.** Kinetic analysis of hOAT1- and rROAT1-mediated transport of cidofovir. hOAT1 and rROAT1 cRNA-injected oocytes were exposed to increasing substrate concentrations (0.002 to 1 mM depending on substrate and transporter) for 20 min. Saturation analysis was performed, and a representative double reciprocal plot with linear regression analysis is shown. The determined $K_{m}$ values for all of the substrates tested are reported in Table 2. The data shown are mean ± S.E. values from three to four animals (10 oocytes/treatment/animal).

**Table 2**

Comparison of hOAT1 and rROAT1 substrate affinity

<table>
<thead>
<tr>
<th>Substrate</th>
<th>hOAT1 $K_{m}$ µM</th>
<th>rROAT1 $K_{m}$ µM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cidofovir</td>
<td>46</td>
<td>238</td>
</tr>
<tr>
<td>Adefovir</td>
<td>30</td>
<td>270</td>
</tr>
<tr>
<td>PAH</td>
<td>4</td>
<td>70</td>
</tr>
</tbody>
</table>

Each $K_{m}$ was determined from a double reciprocal plot of a 20-min uptake at substrate concentrations ranging from 10 to 400 µM for hOAT1 (PAH was 2 to 20 µM because of its lower $K_{m}$) and 50 to 1000 µM for rROAT1. Plotted data were mean ± S.E. values from three to four animals (10 oocytes/concentration/animal), and $K_{m}$ values were rounded to the nearest whole number. $K_{m}$ data of PAH for rROAT1 are reproduced from Sweet et al., 1997.
ence, hOAT1). In addition, clinical pharmacokinetic studies demonstrated that the peak plasma drug levels (C_{max}) generated by therapeutically relevant doses of cidofovir and adefovir are 30 to 40 μM (Cundy et al., 1995b) and 0.5 to 1 μM (Barditch-Crovo et al., 1997), respectively, suggesting that tubular uptake of the two antivirals may proceed below saturation of hOAT1. Therefore, it should be noted that Xenopus oocytes may exhibit a somewhat unique pattern of post-translational modifications, which could result in some functional differences between the native and expressed hOAT1. Therefore, it would be important to study hOAT1 in a more relevant, e.g., mammalian, expression system to confirm the suggested relationship between pharmacokinetics and tubular transport of adefovir and cidofovir. Nevertheless, the findings discussed above argue that hOAT1 can mediate active accumulation of nucleoside phosphonates in human proximal tubules and, thus, may be directly involved in the etiology of cidofovir-and/or adefovir-associated nephrotoxicity.

Besides hOAT1, other renal transporters may also potentially contribute to active tubular accumulation of these drugs. Among others, recently identified rat organic anion transporting polypeptide (oatp) type 3 is expressed almost exclusively in kidney, and transports organic anions like thyroxine or taurocholic acid (Abe et al., 1998). Closely related rat oatp-1 and its human homolog are expressed in liver, as well as in kidney, and transport steroid hormones, sulfobromophthalein, and other organic anions (Jacquemin et al., 1994; Kullak-Ublick et al., 1995). Another renal transporter OAT-K1 transports folate, methotrexate, and nonsteroidal anti-inflammatory drugs (Saito et al., 1996). Some structural similarity was found between OAT-K1, oatp-1, and oatp-3 (Jacquemin et al., 1994; Kullak-Ublick et al., 1995; Saito et al., 1996; Abe et al., 1998). Accordingly, they all exhibit low sensitivity to probenecid and are unable to transport PAH. On the contrary, rOAT-2 expressed in liver and exhibit low sensitivity to probenecid and are unable to transport PAH. Nonetheless, the findings discussed above argue that hOAT1 can mediate active accumulation of nucleoside phosphonates in human proximal tubules and, thus, may be directly involved in the etiology of cidofovir-and/or adefovir-associated nephrotoxicity.

In addition to uptake across the basolateral membrane, efflux across the apical membrane should also influence the steady-state tubular accumulation of nucleoside phosphonates. The accumulation of nucleoside phosphonates in kidney cortex suggests that the luminal efflux is presumably the rate-limiting step in their tubular secretion pathway (Cundy et al., 1996a,b). To date, it is not clear how the apical efflux of PAH functions and whether nucleoside phosphonates share this route with PAH. There are some suggestions that PAH/α-KG exchanger may be present in human renal apical tubular membrane (Roch-Ramel, 1998). However, its relation to hOAT1 remains to be elucidated. Notably, multidrug resistance-associated protein, which mediates ATP-dependent efflux of hydrophobic anions, has been detected in the apical membrane of kidney proximal tubules (Schaub et al., 1997), suggesting that it may be a potential candidate for mediating apical efflux of nucleoside phosphonates.

In summary, we cloned and characterized a human renal organic anion transporter and identified several novel substrates among a class of clinically important antivirals. Further characterization of the substrate specificity of hOAT1 may help to identify new potentially nephrotoxic agents. In addition, progress in elucidation of the structure/function relationships of hOAT1, including identification of its substrate/inhibitor binding domains, will be invaluable toward the rational design of novel, specific, and potent inhibitors that may serve as efficient nephroprotectants.

Acknowledgments

We thank Laura A. Hall from the National Institute of Environmental Health Sciences for invaluable technical assistance with the Xenopus oocyte expression assay experiments. We also thank Norbert Bischofberger and Mick Hitchcock from Gilead Sciences for helpful discussions and critical reading of the manuscript.

References


Send reprint requests to: Dr. Tomas Cihlar, Gilead Sciences, 333 Lakeside Dr., Foster City, CA 94404. E-mail: tomas_cihlar@gilead.com